The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Kristen Pettit, MD
Articles by Kristen Pettit, MD
The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.